Laura E Mccoy

List of Publications by Year
in descending order

39 papers	6,820 citations	218677 26 h-index	315739 38 g-index
51 all docs	51 docs citations	51 times ranked	12687 citing authors

#	Article	IF	Citations
1	Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature, 2022, 601, 110-117.	27.8	280
2	SARS-CoV-2â€“specific memory B cells can persist in the elderly who have lost detectable neutralizing antibodies. Journal of Clinical Investigation, 2022, 132, .	8.2	24
3	SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia, 2021, 35, 289-292.	7.2	26
4	Vaccine responses in ageing and chronic viral infection. Oxford Open Immunology, 2021, 2, .	2.8	3
5	SARS-CoV-2 evolution during treatment of chronic infection. Nature, 2021, 592, 277-282.	27.8	802
6	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593, 136-141.	27.8	648
7	The effect of spike mutations on SARS-CoV-2 neutralization. Cell Reports, 2021, 34, 108890.	6.4	200
8	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. Science Advances, 2021, 7, .	10.3	107
9	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	27.8	549
10	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity, 2021, 54, 1276-1289.e6.	14.3	112
11	Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. Lancet HIV,the, 2021, 8, e317-e318.	4.7	36
12	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. Kidney International Reports, 2021, 6, 1799-1809.	0.8	13
13	Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. , 2021, 3, e0488.		2
14	Sex differences in immunological responses to COVID-19: a cross-sectional analysis of a single-centre cohort. British Journal of Anaesthesia, 2021, 127, e75-e78.	3.4	4
15	Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein. Journal of Virology, 2021, 95, e0009421.	3.4	5
16	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. PLoS Pathogens, 2021, 17, e1009736.	4.7	18
17	Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVIDâ€19 with Bâ€cell malignancies. British Journal of Haematology, 2021, 195, 706-709.	2.5	16
18	Influence of IL-6 levels on patient survival in COVID-19. Journal of Critical Care, 2021, 66, 123-125.	2.2	7

#	Article	IF	Citations
19	To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Frontiers in Immunology, 2021, 12, 708227.	4.8	26
20	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nature Communications, 2021, 12, 5839.	12.8	67
21	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	4.7	105
22	Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science, 2020, 370, 1339-1343.	12.6	735
23	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. Science Advances, 2020, 6, eaba0512.	10.3	18
24	Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. Lancet, The, 2020, 396, e6-e7.	13.7	196
25	Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes. Antibodies, 2019, 8, 38.	2.5	25
26	HIV-1 remission following CCR5Î”32/Î”32 haematopoietic stem-cell transplantation. Nature, 2019, 568, 244-248.	27.8	447
27	The expanding array of HIV broadly neutralizing antibodies. Retrovirology, 2018, 15, 70.	2.0	38
28	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity, 2018, 49, 288-300.e8.	14.3	175
29	Circulating and intrahepatic antiviral B cells are defective in hepatitis B. Journal of Clinical Investigation, 2018, 128, 4588-4603.	8.2	208
30	Identification and specificity of broadly neutralizing antibodies against <scp>HIV</scp>. Immunological Reviews, 2017, 275, 11-20.	6.0	198
31	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity, 2017, 46, 1073-1088.e6.	14.3	286
32	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Reports, 2017, 21, 222-235.	6.4	58
33	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity, 2016, 45, 483-496.	14.3	335
34	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Reports, 2016, 16, 2327-2338.	6.4	216
35	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens, 2015, 11, e1005110.	4.7	78
36	Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity, 2015, 43, 959-973.	14.3	177

#	Article	IF	Citations
37	Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1. PLoS Pathogens, 2014, 10, e1004552.	4.7	34
38	A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition. PLoS Pathogens, 2013, 9, e1003202.	4.7	64
39	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. Journal of Experimental Medicine, 2012, 209, 1091-1103.	8.5	91